Compare AbCellera Biologics Inc (ABCL) vs Marvell Technology Inc (MRVL) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Marvell Technology (MRVL) trades at $230.7, down 5.95% amid a sector-wide chip stock selloff. The stock shows strong earnings beats in recent quarters but faces high valuation multiples with a P/E of 85.7 and P/S of 25.0. Technical indicators are neutral, with support near $234 and resistance at $257. Revenue growth is projected to surge to $8.7B in 2026, with net income turning positive to $2.5B, signaling a potential fundamental turnaround.

Outlook: MRVL's AI infrastructure growth and analyst consensus target of $262.6 offer upside, but high valuations and margin pressures pose risks. Investor sentiment is mixed due to semiconductor volatility, though institutional backing remains strong with 82% buy ratings.